Landmarks trials in pancreatic cancer
Reading File
Reading File
Finding Sources
Searching PubMed
"Pancreatic Neoplasms"[MeSH Terms] AND clinical trial
Searching the Web
pancreatic cancer pivotal randomized trials PRODIGE 24 MPACT POLO NAPOLI 3 official publications
Searching PubMed
pancreatic cancer randomized trial
Landmark trials in pancreatic ductal adenocarcinoma
1. Resected disease: adjuvant therapy
| Trial | Key comparison | Main finding | Why it matters |
|---|---|---|---|
| ESPAC-1 (2004) | Adjuvant chemotherapy and/or chemoradiation after resection | Adjuvant 5-FU-based chemotherapy improved survival; chemoradiation did not show benefit. | Helped establish postoperative systemic chemotherapy and created long-standing caution about routine adjuvant chemoradiation. Neoptolemos et al. |
| CONKO-001 (2007; long-term update 2013) | Gemcitabine vs observation after complete resection | Gemcitabine improved disease-free survival and later showed an overall-survival benefit. | Established 6 months of adjuvant gemcitabine as an early standard. |
| ESPAC-3 (2010) | 5-FU/leucovorin vs gemcitabine | Similar overall survival, but gemcitabine had less serious toxicity. | Supported gemcitabine as the preferred postoperative backbone. |
| ESPAC-4 (2017) | Gemcitabine-capecitabine (GemCap) vs gemcitabine | Median OS: 28.0 vs 25.5 months. | Established GemCap as an adjuvant standard, particularly where modified FOLFIRINOX is unsuitable. ESPAC-4 publication |
| PRODIGE-24/CCTG PA.6 (2018) | Modified FOLFIRINOX vs gemcitabine | Median OS: 54.4 vs 35.0 months; marked improvement in disease-free survival. | Practice-defining. Modified FOLFIRINOX became the preferred adjuvant regimen for fit patients after R0/R1 resection. Conroy et al. |
Practical takeaway: In fit postoperative patients, adjuvant modified FOLFIRINOX is generally the reference regimen. GemCap or gemcitabine alone remain options when fitness, postoperative recovery, or toxicity risk limits FOLFIRINOX.
2. Metastatic disease: first-line systemic therapy
| Trial | Key comparison | Main finding | Why it matters |
|---|---|---|---|
| Burris trial (1997) | Gemcitabine vs 5-FU | Gemcitabine improved clinical benefit response and median survival, although the absolute survival gain was modest. | Made gemcitabine the foundational first-line drug for advanced pancreatic cancer. Burris et al. |
| NCIC CTG PA.3 (2007) | Gemcitabine-erlotinib vs gemcitabine | Statistically significant but very small survival advantage. | Showed that EGFR inhibition has limited clinical value in unselected PDAC; it is rarely a preferred contemporary choice. |
| ACCORD 11/PRODIGE 4 (2011) | FOLFIRINOX vs gemcitabine | Median OS: 11.1 vs 6.8 months; higher response rate but greater toxicity. | Established FOLFIRINOX as a first-line standard for patients with good performance status. Conroy et al. |
| MPACT (2013) | Nab-paclitaxel plus gemcitabine vs gemcitabine | Median OS: 8.5 vs 6.7 months. | Established gemcitabine plus nab-paclitaxel as another major first-line standard. Von Hoff et al. |
| NAPOLI-3 (2023) | NALIRIFOX vs gemcitabine-nab-paclitaxel | Median OS: 11.1 vs 9.2 months. | Established NALIRIFOX as an additional first-line option for metastatic disease. Wainberg et al. |
Practical takeaway: Modern first-line choices for metastatic PDAC include FOLFIRINOX, NALIRIFOX, and gemcitabine-nab-paclitaxel. Selection is driven by performance status, bilirubin level, neuropathy risk, comorbidity, prior therapy, and patient priorities.
3. Metastatic disease: maintenance and biomarker-directed treatment
| Trial | Population and comparison | Main finding | Why it matters |
|---|---|---|---|
| POLO (2019) | Germline BRCA1/2-mutated metastatic PDAC without progression after platinum chemotherapy: maintenance olaparib vs placebo | Median PFS: 7.4 vs 3.8 months. Initial overall-survival benefit was not demonstrated. | Established maintenance olaparib for the selected germline BRCA-mutated, platinum-sensitive population. It made germline testing clinically actionable. Golan et al. |
Related principle: All patients with pancreatic adenocarcinoma should be considered for germline testing, and tumors should undergo molecular profiling where feasible. Actionable subsets are uncommon but include BRCA1/2 or PALB2-related homologous-recombination deficiency, MSI-H/dMMR disease, NTRK fusions, KRAS G12C, and selected HER2-altered tumors.
4. Metastatic disease: second-line treatment
| Trial | Key comparison | Main finding | Why it matters |
|---|---|---|---|
| CONKO-003 | OFF regimen, oxaliplatin plus 5-FU/leucovorin, vs 5-FU/leucovorin after gemcitabine | Improved survival after gemcitabine failure. | Provided early evidence supporting oxaliplatin-fluoropyrimidine treatment in the second line. |
| NAPOLI-1 (2016) | Liposomal irinotecan plus 5-FU/leucovorin vs 5-FU/leucovorin after gemcitabine | Median OS: 6.1 vs 4.2 months. | Established nal-IRI plus 5-FU/leucovorin as a standard option after gemcitabine-based therapy. Wang-Gillam et al. |
| PANCREOX (2016) | mFOLFOX6 vs 5-FU/leucovorin after gemcitabine | No benefit and worse survival/toxicity with mFOLFOX6 in this trial. | A caution against assuming all oxaliplatin-fluoropyrimidine regimens are interchangeable. |
Practical takeaway: Sequence therapies by avoiding immediate reuse of the same drug class. For example, after gemcitabine-nab-paclitaxel, nal-IRI plus 5-FU/leucovorin is commonly used; after FOLFIRINOX, gemcitabine-based therapy is often used.
5. Locally advanced and borderline-resectable disease
| Trial | Key question | Main finding | Significance |
|---|---|---|---|
| LAP07 (2016) | After induction gemcitabine-based therapy, does consolidation chemoradiotherapy improve survival compared with continuing chemotherapy? | No overall-survival benefit from chemoradiotherapy. | Chemoradiation is not routine for all locally advanced cases, though it may be considered selectively for local control after systemic therapy. Hammel et al. |
| PREOPANC (2020; long-term results 2022) | Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery vs immediate surgery | Improved R0 resection rate and long-term overall survival in the neoadjuvant strategy. | A major randomized argument for preoperative therapy, especially in borderline-resectable disease. Long-term PREOPANC results |
| Alliance A021501 (2022) | Neoadjuvant mFOLFIRINOX alone vs mFOLFIRINOX plus hypofractionated radiotherapy in borderline-resectable PDAC | The radiotherapy-containing arm did not meet the prespecified efficacy target. | Supports neoadjuvant mFOLFIRINOX alone as a reference approach; routine addition of radiation remains unproven. |
High-yield “must know” list
If you need only the core exam or viva list, learn these first:
- Burris 1997: gemcitabine over 5-FU in advanced disease.
- CONKO-001: adjuvant gemcitabine after resection.
- ESPAC-4: adjuvant GemCap over gemcitabine.
- PRODIGE-24: adjuvant modified FOLFIRINOX over gemcitabine.
- ACCORD 11/PRODIGE 4: FOLFIRINOX over gemcitabine in metastatic PDAC.
- MPACT: gemcitabine-nab-paclitaxel over gemcitabine.
- NAPOLI-1: nal-IRI plus 5-FU/leucovorin after gemcitabine.
- POLO: maintenance olaparib in germline BRCA-mutated platinum-sensitive metastatic disease.
- LAP07: no routine survival advantage for consolidative chemoradiation in locally advanced PDAC.
- PREOPANC: supports neoadjuvant therapy in resectable/borderline-resectable settings.
- NAPOLI-3: NALIRIFOX over gemcitabine-nab-paclitaxel in first-line metastatic PDAC.
A recent trial-landscape review is Sarfraz et al., 2024, PMID 38976079. Its emphasis on immunotherapy trials should not be interpreted as evidence that checkpoint inhibitors work broadly in PDAC: outside rare biomarkers such as MSI-H/dMMR, benefit remains limited.
Land mark trials in pancreatic cancer
Reading File
Finding Sources
Searching PubMed
pancreatic cancer landmark randomized trials
Searching PubMed
pancreatic cancer treatment systematic review
Searching the Web
pancreatic cancer clinical practice guideline treatment PRODIGE 24 NAPOLI-3 2025
Landmark trials in pancreatic ductal adenocarcinoma
Adjuvant treatment after resection
| Trial | Comparison | Key result | Practice impact |
|---|---|---|---|
| CONKO-001 | Gemcitabine vs observation | Improved disease-free survival and long-term overall survival. | Established adjuvant gemcitabine. |
| ESPAC-3 | 5-FU/leucovorin vs gemcitabine | Similar survival; gemcitabine had a more favorable toxicity profile. | Confirmed gemcitabine as a postoperative standard. |
| ESPAC-4 | Gemcitabine-capecitabine vs gemcitabine | Median OS 28.0 vs 25.5 months. | Established GemCap as an adjuvant option. ESPAC-4 |
| PRODIGE-24/CCTG PA.6 | Modified FOLFIRINOX vs gemcitabine | Median OS 54.4 vs 35.0 months. | Practice-defining trial: modified FOLFIRINOX is preferred adjuvant therapy for fit patients. PRODIGE-24 |
First-line metastatic disease
| Trial | Comparison | Key result | Practice impact |
|---|---|---|---|
| Burris et al. | Gemcitabine vs 5-FU | Improved clinical-benefit response and modest survival benefit. | Gemcitabine became the early backbone of treatment. Burris trial |
| ACCORD-11/PRODIGE-4 | FOLFIRINOX vs gemcitabine | Median OS 11.1 vs 6.8 months. | Established FOLFIRINOX for fit patients with metastatic PDAC. Conroy et al. |
| MPACT | Gemcitabine plus nab-paclitaxel vs gemcitabine | Median OS 8.5 vs 6.7 months. | Established gemcitabine-nab-paclitaxel as a first-line standard. MPACT trial |
| NAPOLI-3 | NALIRIFOX vs gemcitabine-nab-paclitaxel | Median OS 11.1 vs 9.2 months. | Added NALIRIFOX as a first-line metastatic option. NAPOLI-3 |
Maintenance and precision treatment
| Trial | Population and intervention | Key result | Practice impact |
|---|---|---|---|
| POLO | Germline BRCA1/2-mutated metastatic PDAC, non-progressive after platinum: maintenance olaparib vs placebo | Median PFS 7.4 vs 3.8 months; no clear overall-survival advantage. | Supports maintenance olaparib in this selected subgroup and reinforces universal germline testing. POLO trial |
Second-line metastatic disease
| Trial | Comparison | Key result | Practice impact |
|---|---|---|---|
| CONKO-003 | OFF, oxaliplatin plus 5-FU/leucovorin, vs 5-FU/leucovorin after gemcitabine | Survival benefit with OFF. | Established a fluoropyrimidine-oxaliplatin strategy after gemcitabine. |
| NAPOLI-1 | Liposomal irinotecan plus 5-FU/leucovorin vs 5-FU/leucovorin after gemcitabine | Median OS 6.1 vs 4.2 months. | Established nal-IRI plus 5-FU/leucovorin as a standard post-gemcitabine regimen. NAPOLI-1 |
| PANCREOX | mFOLFOX6 vs 5-FU/leucovorin after gemcitabine | Worse survival and more toxicity with mFOLFOX6. | Important negative trial: oxaliplatin regimens are not interchangeable. |
Neoadjuvant and locally advanced disease
| Trial | Clinical setting | Key finding | Take-home point |
|---|---|---|---|
| PREOPANC | Resectable or borderline-resectable PDAC | Neoadjuvant gemcitabine-based chemoradiotherapy improved R0 resections and long-term survival over upfront surgery. | Supports a preoperative strategy, especially for borderline-resectable tumors. PREOPANC long-term results |
| LAP07 | Locally advanced PDAC after induction chemotherapy | Chemoradiotherapy did not improve overall survival compared with continued chemotherapy. | Radiation is selective for local control, not routine for all locally advanced cases. LAP07 |
| Alliance A021501 | Borderline-resectable PDAC | Neoadjuvant mFOLFIRINOX alone performed better than the strategy adding hypofractionated radiotherapy. | Routine preoperative radiotherapy after mFOLFIRINOX remains unproven. |
Viva or exam essentials
- Burris 1997: gemcitabine replaced 5-FU as the basic systemic-treatment standard.
- ACCORD-11: FOLFIRINOX improved survival in metastatic disease.
- MPACT: gemcitabine-nab-paclitaxel improved survival in metastatic disease.
- PRODIGE-24: modified FOLFIRINOX is the major adjuvant standard in fit resected patients.
- ESPAC-4: GemCap is an important adjuvant alternative.
- NAPOLI-1: nal-IRI plus 5-FU/leucovorin after gemcitabine failure.
- POLO: maintenance olaparib for germline BRCA-mutated, platinum-sensitive metastatic PDAC.
- PREOPANC: supports neoadjuvant treatment, particularly in borderline-resectable disease.
- LAP07: no routine overall-survival gain from consolidative chemoradiation in locally advanced disease.
- NAPOLI-3: NALIRIFOX is a first-line option in metastatic PDAC.
Textbook context supports FOLFIRINOX or gemcitabine-nab-paclitaxel as key first-line systemic options, with liposomal irinotecan plus 5-FU/leucovorin active after prior gemcitabine therapy - Goldman-Cecil Medicine, section “Unresectable or Metastatic Disease.”
This is a shared conversation. Sign in to Orris to start your own chat.